Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2005
05/25/2005EP1532986A2 Pharmaceutical composition for treatment of rhinitis
05/25/2005EP1532981A1 Stable eye drops containing latanoprost as the active ingredient
05/25/2005EP1532979A1 Drug composition for blood sugar control
05/25/2005EP1532978A1 Remedy for urinary frequency and urinary incontinence
05/25/2005EP1532977A1 Antifungal agents for external use
05/25/2005EP1532976A2 Compositions comprising organic disulfides, cysteine sulfoxides, sulfones, sulfoximines or other sulfur containing substances and their use in therapy in combination with radiation
05/25/2005EP1532975A1 Process for the manufacture of free-flowing, powdery atorvastatin adsorbates
05/25/2005EP1532974A2 Aqueous gel comprising 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
05/25/2005EP1532434A1 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
05/25/2005EP1532279A2 Method, composition and kit for antigenic binding of norwalk-like viruses
05/25/2005EP1532271A2 Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
05/25/2005EP1532249A2 Rnai probes targeting cancer-related proteins
05/25/2005EP1532248A1 Modified small interfering rna molecules and methods of use
05/25/2005EP1532246A2 Genetic suppression and replacement
05/25/2005EP1532176A2 Cd200-receptor mediated modulation of bone development
05/25/2005EP1532161A2 Vectors for expression of hml-2 polypeptides
05/25/2005EP1532159A2 Scaffolded maleimide clusters for multivalent peptide assembly
05/25/2005EP1532155A2 C6- AND C9-SUBSTITUTED CHROMENO[4,3-c]ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS
05/25/2005EP1532154A1 Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
05/25/2005EP1532153A1 Azepinoindole and pyridoindole derivatives as pharmaceutical agents
05/25/2005EP1532152A1 Novel polymorph of n-methyl-n-(3- 3- 2-thienylcarbonyl]-pyrazol- 1,5-alpha]-pyrimidin-7-yl phenyl)acetamide and compositions and methods related thereto
05/25/2005EP1532148A1 Novel purine- or pyrrolol(2,3-d)pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity
05/25/2005EP1532147A1 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
05/25/2005EP1532145A1 Pyrazole compositions useful as inhibitors of gsk-3
05/25/2005EP1532144A1 Novel quinuclidine derivatives and their use
05/25/2005EP1532142A2 Polypeptide cleavage process
05/25/2005EP1532141A1 2-pyrrolidin-2-yl- 1,3,4]-oxadiazole derivatives and the use of the same as antidepressants
05/25/2005EP1532139A1 Total synthesis of myriaporones
05/25/2005EP1532138A1 Inhibitors of tyrosine kinases
05/25/2005EP1532137A2 Antimicrobial aza-bicyclic derivates, their compositions and uses
05/25/2005EP1532135A1 Nf-kb inhibitors
05/25/2005EP1532134A1 Novel thiophene acyl hydrazino derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use
05/25/2005EP1532133A1 Nf-:b inhibitors
05/25/2005EP1532132A1 Novel benzodioxoles
05/25/2005EP1532131A2 Motilide compounds
05/25/2005EP1532130A1 Process for the production of an immunosuppressant
05/25/2005EP1532124A1 Novel compounds
05/25/2005EP1532122A1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
05/25/2005EP1532121A1 New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
05/25/2005EP1532118A2 Imidazole compounds for the treatment of hepatitis c virus infections
05/25/2005EP1532117A1 Multi-substituded imidazolines and method of use thereof
05/25/2005EP1532115A2 Protease inhibitors
05/25/2005EP1532111A1 2,5-disubstituted 3-mercaptopentanoic acid
05/25/2005EP1532109A1 Pyrrolidine derivatives as oxytocin antagonists
05/25/2005EP1532108A2 Structural carotenoid analogs for the inhibition and amelioration of disease
05/25/2005EP1532105A1 Anthranyl derivatives having an anticholecystokinin activity (anti-cck-1), a process for their preparation, and pharmaceutical use thereof
05/25/2005EP1532104A1 Crystalline beta-2 adrenergic receptor agonist
05/25/2005EP1532103A2 Use of compounds having an amine nucleus in manufacture of a medicament useful for treating factor viia-associated conditions
05/25/2005EP1532102A1 Cosmetic or dermopharmaceutical compositions comprising tyramine derivatives, method for preparing same, and use thereof
05/25/2005EP1532098A1 Process for preparing nitrooxyderivatives of naproxen
05/25/2005EP1531906A1 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor
05/25/2005EP1531879A1 Use of organic compounds
05/25/2005EP1531874A1 Embolization
05/25/2005EP1531873A2 Agent delivery particle
05/25/2005EP1531869A2 Compositions and methods for treating cancer using maytansinoid cd44 antibody immunoconjugates and chemotherapeutic agents
05/25/2005EP1531868A2 Therapeutic agent-containing polymeric nanoarticles
05/25/2005EP1531867A1 Metastable pharmaceutical compositions
05/25/2005EP1531866A1 Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
05/25/2005EP1531854A2 O-derivatized nocathiacin derivatives
05/25/2005EP1531851A2 Covalent conjugates between artemisinin-related endoperoxides and iron-carrying proteins and methods of use
05/25/2005EP1531844A2 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
05/25/2005EP1531843A1 Method for treating cervical cancer
05/25/2005EP1531842A2 Regulation of cell growth by muc1
05/25/2005EP1531839A1 Avian appeasing pheromones to decrease stress, anxiety and aggressiveness
05/25/2005EP1531837A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
05/25/2005EP1531835A2 Micelle assemblies
05/25/2005EP1531832A1 Therapeutic compositions for use in prophylaxis or treatment of diarrheas
05/25/2005EP1531831A1 Fosinopril formulation
05/25/2005EP1531830A1 Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations
05/25/2005EP1531829A2 Infertility treatment with exemestane
05/25/2005EP1531828A2 Methods of treating bacterial infections and diseases associated therewith
05/25/2005EP1531826A2 Prophylaxis and treatment of infectious diseases
05/25/2005EP1531825A2 Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases
05/25/2005EP1531824A2 Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders
05/25/2005EP1531823A2 Flavin n-oxides: new anti-cancer agents and pathogen eradication agents
05/25/2005EP1531819A1 USE OF I kappa B KINASE INHIBITORS FOR THE TREATMENT OF PAIN
05/25/2005EP1531818A1 Topical treatment of skin diseases
05/25/2005EP1531817A1 Glycinamide derivatives as raf-kinase inhibitors
05/25/2005EP1531816A1 Spirocyclic piperidines as mch1 antagonists and uses thereof
05/25/2005EP1531815A1 Glucokinase activators
05/25/2005EP1531814A1 Sustained-release tablet composition of pramipexole
05/25/2005EP1531813A1 Use of compounds for increasing spermatozoa motility
05/25/2005EP1531812A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
05/25/2005EP1531811A2 Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer
05/25/2005EP1531810A2 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
05/25/2005EP1531809A1 At1-receptor antagonists for preventing secondary strokes
05/25/2005EP1531808A1 Peroxynitrite rearrangement catalysts used for the treatment or prophylaxis of diseases caused by peroxynitrite-mediated reactions
05/25/2005EP1531807A1 Bazedoxifene treatment regimens
05/25/2005EP1531806A2 Use of thio-oxindole derivatives in treatment of hormone-related conditions
05/25/2005EP1531805A1 Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent
05/25/2005EP1531804A1 Method of inhibiting angiogenesis
05/25/2005EP1531803A1 Method of inhibiting prostate cancer cell proliferation
05/25/2005EP1531802A1 Pharmaceutical formulations comprising combinations of epinastine, pseudoephedrine and methylephedrine
05/25/2005EP1531801A1 Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
05/25/2005EP1531800A2 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
05/25/2005EP1531799A1 Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
05/25/2005EP1531798A2 Pulmonary delivery for levodopa
05/25/2005EP1531797A1 Biodegradable block copolymeric compositions for drug delivery
05/25/2005EP1531795A1 Formulations limiting spread of pulmonary infections
05/25/2005EP1531794A2 Inhalable epinephrine
1 ... 4679 4680 4681 4682 4683 4684 4685 4686 4687 4688 4689 4690 4691 4692 4693 4694 4695 4696 4697 4698 4699 ... 7860